MDT
86.43
+1.23%↑
A
115.04
+1.61%↑
VEEV
175.23
-0.24%↓
HQY
83.43
+1.34%↑
PHR.US
8.44
+3.18%↑
MDT
86.43
+1.23%↑
A
115.04
+1.61%↑
VEEV
175.23
-0.24%↓
HQY
83.43
+1.34%↑
PHR.US
8.44
+3.18%↑
MDT
86.43
+1.23%↑
A
115.04
+1.61%↑
VEEV
175.23
-0.24%↓
HQY
83.43
+1.34%↑
PHR.US
8.44
+3.18%↑
MDT
86.43
+1.23%↑
A
115.04
+1.61%↑
VEEV
175.23
-0.24%↓
HQY
83.43
+1.34%↑
PHR.US
8.44
+3.18%↑
MDT
86.43
+1.23%↑
A
115.04
+1.61%↑
VEEV
175.23
-0.24%↓
HQY
83.43
+1.34%↑
PHR.US
8.44
+3.18%↑
24 val.
Dabar
Min
Max
Pajamos | 13M 12M |
|---|---|
Pardavimai | 8.1M 34M |
P/E Sektoriaus vid. | 6.978 57.05 |
Pelno marža | 35.648 |
Darbuotojai | 61 |
EBITDA | 8.2M 9.7M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +154.4% upside |
Kitas uždarbis | 2026-05-12 |
|---|
Rinkos kapitalizacija | 40M 553M |
|---|---|
Ankstesnė atidarymo kaina | 0 |
Ankstesnė uždarymo kaina | 0 |
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
2026-03-31 23:31; UTC
Stocks to Watch: Nike, RH, NCino
DJ
Skaityti
2026-03-31 22:35; UTC
Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update
DJ
Skaityti
2026-04-01 00:00; UTC
The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ
DJ
Skaityti
2026-03-31 23:50; UTC
Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO
DJ
Skaityti
2026-03-31 23:43; UTC
Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk
DJ
Skaityti
2026-03-31 23:33; UTC
Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk
DJ
Skaityti
2026-03-31 23:21; UTC
Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com
DJ
Skaityti
2026-03-31 23:14; UTC
Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk
DJ
Skaityti
2026-03-31 23:12; UTC
Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke 2025 Loss Widens >000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ
DJ
Skaityti
2026-03-31 22:36; UTC
China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ
DJ
Skaityti
2026-03-31 21:46; UTC
Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ
DJ
Skaityti
2026-03-31 21:36; UTC
West African Resources's Costs Higher Than Bull Expected -- Market Talk
DJ
Skaityti
2026-03-31 21:35; UTC
Nike Expects China Sales Down 20% in 4Q, CFO Says
DJ
Skaityti
2026-03-31 21:35; UTC
Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says
DJ
Skaityti
2026-03-31 21:35; UTC
Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says
DJ
Skaityti
2026-03-31 21:33; UTC
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com
DJ
Skaityti
2026-03-31 21:33; UTC
Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says
DJ
Skaityti
2026-03-31 21:32; UTC
Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says
DJ
Skaityti
2026-03-31 21:28; UTC
Nike Expects to End 4Q With Elevated Inventory, CFO Says
DJ
Skaityti
2026-03-31 21:26; UTC
Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says
DJ
Skaityti
2026-03-31 21:25; UTC
Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says
DJ
Skaityti
2026-03-31 21:24; UTC
Nike: Turnaround Plan Progressing at Different Rates -- Market Talk
DJ
Skaityti
2026-03-31 21:22; UTC
Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters
DJ
Skaityti
2026-03-31 21:22; UTC
Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says
DJ
Skaityti
2026-03-31 21:21; UTC
Nike's Digital Channel Still Too Promotional, CFO Says
DJ
Skaityti
2026-03-31 21:20; UTC
Nike CEO: Converse Remains Important to Portfolio
DJ
Skaityti
Kainos pokytis
By TipRanks
12 mėnesių prognozė
Vidutinis 23.71 USD 154.4%
Aukščiausias 26 USD
Žemiausias 21 USD
Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines KemPharm Inc kainas – Dist per pastaruosius 3 mėnesius.
By TipRanks
Stiprus pirkimas
8 ratings
8
Pirkti
0
Laikyti
0
Parduoti
Remiantis 8 analitikų, pateikusių KemPharm Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$